Covaxin shows 78% efficacy in Phase 3 interim analysis, says Bharat Biotech

The Phase 3 study enrolled 25,800 participants between 18-98 years of age, including 10% over the age of 60, says the Hyderabad-based firm

Indigenously developed Covid-19 vaccine, Covaxin, demonstrated overall interim clinical efficacy of 78% in Phase 3 trials, said Bharat Biotech and ICMR on Wednesday. 

Bharat Biotech's Covaxin has received Emergency Use Authorizations (EUAs) for COVID-19 treatment in India and in several countries across the globe with another 60 in the process.

"The second interim analysis is based on accruing more than 87 symptomatic cases of Covid-19. Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78% against mild, moderate, and severe Covid-19 disease," said Hyderabad-based Bharat Biotech in a